Efficacy and Safety of Bivalirudin versus Heparin Plus Tirofiban in Elderly Patients with Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary InterventionKe Zhu, Wen Lu, Yi-jie Huang, Lin-guang Wang, Qiang Wu, Chun-guang Feng and Qiang Fu*
Department of Cardiology, Xuzhou Hospital Affiliated East South University School of Medicine, Xuzhou Cardiovascular Disease Institute, PR China
- *Corresponding Author:
- Qiang Fu
Department of Cardiology
Xuzhou Hospital Affiliated East South University School of Medicine
Xuzhou Cardiovascular Disease Institute, 199 Jiefang Road
Xuzhou 221009, PR China
Tel: +86 18952170277
E-mail: [email protected]
Received Date: January 21, 2016; Accepted Date: February 01, 2016; Published Date: February 08, 2016
Citation: Zhu K, Lu W, Huang Y, Wang L, Wu Q, et al. (2016) Efficacy and Safety of Bivalirudin versus Heparin Plus Tirofiban in Elderly Patients with Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Cardiovasc Pharm Open Access 5:172. doi:10.4172/2329-6607.1000172
Copyright: © 2016 Zhu K, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Objective: The aim of this study was to investigate the antithrombotic effect and safety of Bivalirudin compared with heparin plus Tirofiban in elderly patients with acute myocardial infarction undergoing primary Percutaneous Coronary Intervention (PCI). Methods: One hundred and twenty elderly patients were randomly assigned to receive two different antithrombotic therapies (Group A: Bivalirudin alone or Group B: Heparin plus Tirofiban) in a 1:1 ratio according to the treatment sequence and a table of random numbers. The clinical information, routine examination results, infarct-related sites of the enrolled patients were recorded, and the Thrombolysis in Myocardial Infarction (TIMI) flow grade and other safety indexes after PCI were analyzed. Results: No statistically significant differences existed in ST-segment depression at 2 h after intervention, post- PCI TIMI flow grade and reduction of N-terminal pro-B type natriuretic peptide (NT-proBNP) serum concentrations in patients on day 7 versus day 1 after PCI between the two groups (P>0.05). However, the adverse clinical events of bleeding showed significant differences in the two groups (P<0.05). Conclusion: Bivalirudin exerts confirmed anticoagulant effect and indicates lower risk of bleeding compared with heparin plus Tirofiban in elderly patients with acute myocardial infarction undergoing primary PCI.